MSB 3.21% $1.13 mesoblast limited

Cell Therapy News/Articles, page-18012

  1. 5,838 Posts.
    lightbulb Created with Sketch. 2110
    Remestemcel will definitely be approved, and

    Rexlemostrocel will receive accelerated approval in 2025.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.